Key result
Oral aspirin shows no consistent benefit over placebo for embolic events in infective endocarditis.
Why the study?
The role of aspirin in preventing embolic events in infective endocarditis is controversial, with concerns about bleeding risk limiting its use.
Does oral aspirin reduce the incidence of embolic events in patients with infective endocarditis?
Meta-Analysis (n=1,174)
Does oral aspirin reduce the incidence of embolic events in patients with infective endocarditis?
Routine use of oral aspirin for the prevention of embolic events in infective endocarditis is not recommended due to inconsistent efficacy and potential non-significant increases in bleeding and mortality.
Answers are grounded in this paper and cite their sources.
Does not support routine aspirin for embolic prevention in infective endocarditis; leaves open the need for larger definitive trials.
Infective endocarditis (IE) involves inflammation of the heart's inner lining and valves, leading to complications like embolic events. The role of aspirin in preventing these events is controversial, with concerns about bleeding risk, limiting its use. This meta-analysis evaluates the effectiveness of oral aspirin in preventing embolic events and its adverse outcomes in IE patients. A systematic search was conducted on July 20, 2024, across PubMed/MEDLINE, Cochrane, Scopus, Web of Science, EMBASE, and CINAHL for studies comparing aspirin to placebo or no treatment. The protocol was registered in PROSPERO (CRD42024573274). Five studies involving 1,174 participants were included, with three eligible for meta-analysis due to data limitations. Findings on embolic event incidence were inconsistent: one randomized clinical trial (RCT) excluding prior aspirin therapy (OR 1.62, [0.68-3.86], p = 0.29) and a reanalysis examining long-term use (OR 0.80, [0.36–1.78], p = 0.582) found no significant reduction, while another study reported a possible reduction (OR 0.65, [0.43-0.98], p = 0.04). Bleeding rates trended higher in aspirin groups across two studies, though not statistically significant. Mortality data also varied; one study found higher mortality in aspirin users, while another associated chronic antiplatelet therapy with lower mortality, particularly with early initiation after admission. Aspirin may reduce embolic events in IE, but evidence remains inconclusive due to mixed findings. Aspirin showed a non-significant increase in bleeding risk and mortality, so routine use for embolic prevention in IE is not recommended, highlighting the need for further research to clarify its potential role. • Oral aspirin may be effective in reducing the incidence of embolic events in patients with infective endocarditis (IE) • Aspirin does not significantly increase bleeding risk in IE patients. • Non-statistically significant increase in mortality risk associated with aspirin use.
No takes yet. Share an insight, caveat, or question.
Salazar-Ore et al. (2025) conducted a meta-analysis in Infective endocarditis (n=1,174). Oral aspirin vs. Placebo or no treatment was evaluated on Embolic events. Oral aspirin had inconsistent effects on embolic events in infective endocarditis and was associated with non-significant increases in bleeding and mortality risks.
Synapse has enriched 10 related papers. Consider them for comparative context: